Conditions: Non-diabetic Nephropathy With Hypertension
Keywords: Candesartan Cilexetil Non-diabetic Nephropathy hypertension urine protein creatinine ratio
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 128
Healthy volunteers: no

Brief summary:
To determine the effective dose of candesartan cilexetil for reduction of urinary protein excretion in hypertensive patients with non-diabetic chronic kidney disease with baseline urinary protein/creatinine ratio between 500mg/g and 5000mg/g, by assessing the change in urinary protein/creatinine ratio from baseline to the end of 28-week treatment

Detailed description:

Arms:
arm 1: Candesartan Cilexetil arm 2: Candesartan Cilexetil arm 3: Candesartan Cilexetil

Interventions: intervention 1: Candesartan Cilexetil intervention 2: Candesartan Cilexetil intervention 3: Candesartan Cilexetil 32mg
Intervention descriptions: intervention 1: 8 mg oral once daily dose intervention 2: 16 mg oral once daily dose intervention 3: 32 mg oral once daily dose

Protocol document: